Table 2.

Hyperglycemia during therapy (n =160) using multivariate logistic regression.

Variable	OR (95% CI)	p Value
Age at diagnosis (for increase of 10 year)	1.1 (0.8, 1.6)	.4901
IPI score (ref: 1 or 2)		.5313
≥3	1.5 (0.6, 3.7)
NA/unknown	0.7 (0.2, 2.9)
Type of chemotherapy received (ref: R-CHOP)		.0433
R-EPOCH	2.4 (1.0, 5.6)
History of hypertension prior to therapy (ref: no)		.3592
Yes	1.6 (0.6, 4.1)
History of hyperlipidemia prior to therapy (ref: no)		.7788
Yes	0.9 (0.3, 2.2)
History of diabetes prior to therapy (ref: no)		<.0001
Yes	12.7 (4.2, 38.6)
Pre-PET fasting blood glucose DM status (ref: <100)		.0045
≥100	3.9 (1.5, 10.0)
Unknown	4.8 (1.6, 14.0)

OR: odds ratio; CI: confidence interval; IPI: International Prognostic Index; R-CHOP: rituximab, cyclophosphamide, doxorubicin, prednisone; R-EPOCH: rituximab, etoposide, cyclophosphamide, doxorubicin, prednisone; PET: positron emission tomography; ref: reference; n: number of patients; DM: diabetes mellitus.